bronchial asthma
Conditions
Interventions
None listed
Sponsors
Japanese Red Cross Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with bronchial asthma according to general allergy guideline 2016 2) Patients with bronchial asthma using high-dose inhaled corticosteroids and long-acting beta 2 agonists 3) Patients who obtain written consent regarding the participation of this study
Exclusion criteria
Exclusion criteria: 1) Patients who have previously received benralizumab 2) Patients with severe complications such as heart disease, liver disease or kidney failure 3) Patients judged unsuitable as subjects by doctor's judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship between effect predictors before administration and improvement of symptoms after 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Improvement of questionnaire on quality of life (AQLQ), asthma control test (ACT) score, exacerbation frequency, respiratory function one second amount (FEV 1), divided into two groups at the median of various effect predicting factors before administration 2. The relationship between the variation of various indices and the improvement of AQLQ score, ACT score, exacerbation frequency, FEV 1 3. The time course of various effect predictors 4. Asthma control (the ratio of the number of strokes up to the 12th week, the ratio of unscheduled outpatient visits to the 12th week (including emergency outpatient visits)) 5. Effect of drug reduction scale 6. The incidence of adverse events of Grade 1 or higher during treatment 7. When continuing treatment with benralizumab after 12 weeks, adverse events from the onset of treatment of benralizumab to one year | — |
Countries
Japan
Contacts
Public ContactTakehiro Izumo
Japanese Red Cross Medical Center Respiratory Medicine
Outcome results
None listed